{"id":1020953,"date":"2026-11-13T09:28:49","date_gmt":"2026-11-13T14:28:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/"},"modified":"2026-11-13T09:28:49","modified_gmt":"2026-11-13T14:28:49","slug":"pharmacyte-biotech-reports-strong-cash-and-asset-position","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/","title":{"rendered":"PharmaCyte Biotech Reports Strong Cash and Asset Position"},"content":{"rendered":"

<\/p>\n

PharmaCyte Biotech Reports Strong Cash and Asset Position<\/b><\/p>\n

As reported in its Form 10-Q for the latest quarter, the Company maintains more than $17 million in cash with total assets over $36 million<\/i><\/p>\n

LAS VEGAS–(BUSINESS WIRE<\/a>)–
\nPharmaCyte Biotech, Inc. (Nasdaq:PMCB) (\u201cPharmaCyte\u201d or the \u201cCompany\u201d) today provided an update on its financial position. As reported in the Company\u2019s Quarterly Report on Form 10-Q<\/a> for the quarter ended July 31, 2026 (PMCB\u2019s fiscal year ends April 30), PharmaCyte held total assets of approximately $36.7 million, including approximately $17.7 million in cash and cash equivalents. Stockholders\u2019 equity totaled approximately $27.5 million as of July 31, 2026. PharmaCyte has approximately 566,000 shares of common stock outstanding.<\/p>\n

\n\u201cOur balance sheet is the foundation of PharmaCyte\u2019s strategy,\u201d said Josh Silverman, PharmaCyte Chief Executive Officer. \u201cWith $17.7 million in cash and more than $36 million in total assets, we have the capital to deploy with discipline and to pursue opportunities designed to create value for our shareholders.\u201d<\/p>\n

\nPharmaCyte plans to continue pursuing value-accretive investment opportunities and disciplined operational management to further enhance shareholder returns.<\/p>\n

About PharmaCyte Biotech, Inc.<\/b><\/p>\n

\nPharmaCyte Biotech, Inc. (Nasdaq:PMCB) is a biotechnology company focused on developing cellular therapies for cancer, diabetes and other serious diseases. In parallel, the Company employs a disciplined investment strategy designed to strengthen its financial position and maximize shareholder value through strategic cash deployment.<\/p>\n

Safe Harbor<\/b><\/p>\n

\nThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of PharmaCyte\u2019s management and Board of Directors. Any statements contained in this press release which do not describe historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, whether our exploration of additional opportunities to create new paths toward shareholder value is successful, the effect of the reverse stock split on the market price and liquidity of our common stock and our ability to regain and maintain compliance with Nasdaq listing requirements, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise. More information about PharmaCyte Biotech can be found at https:\/\/pharmacyte.com<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261113547352\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/b>
CORE IR
\n
ir@pharmacyte.com<\/a><\/p>\n

Media Contact:
\n<\/b>
Jules Abraham
\n
CORE IR
\n
516.222.2560
\n
julesa@coreir.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Nevada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

PharmaCyte Biotech Reports Strong Cash and Asset Position As reported in its Form 10-Q for the latest quarter, the Company maintains more than $17 million in cash with total assets over $36 million LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (\u201cPharmaCyte\u201d or the \u201cCompany\u201d) today provided an update on its financial position. As reported in the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 (PMCB\u2019s fiscal year ends April 30), PharmaCyte held total assets of approximately $36.7 million, including approximately $17.7 million in cash and cash equivalents. Stockholders\u2019 equity totaled approximately $27.5 million as of July 31, 2026. PharmaCyte has approximately 566,000 shares of common stock outstanding. \u201cOur balance sheet is the foundation of PharmaCyte\u2019s … <\/p>\n

Continue reading “PharmaCyte Biotech Reports Strong Cash and Asset Position”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1020953","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPharmaCyte Biotech Reports Strong Cash and Asset Position - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PharmaCyte Biotech Reports Strong Cash and Asset Position - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PharmaCyte Biotech Reports Strong Cash and Asset Position As reported in its Form 10-Q for the latest quarter, the Company maintains more than $17 million in cash with total assets over $36 million LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (\u201cPharmaCyte\u201d or the \u201cCompany\u201d) today provided an update on its financial position. As reported in the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 (PMCB\u2019s fiscal year ends April 30), PharmaCyte held total assets of approximately $36.7 million, including approximately $17.7 million in cash and cash equivalents. Stockholders\u2019 equity totaled approximately $27.5 million as of July 31, 2026. PharmaCyte has approximately 566,000 shares of common stock outstanding. \u201cOur balance sheet is the foundation of PharmaCyte\u2019s … Continue reading "PharmaCyte Biotech Reports Strong Cash and Asset Position"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-13T14:28:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PharmaCyte Biotech Reports Strong Cash and Asset Position\",\"datePublished\":\"2026-11-13T14:28:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/\"},\"wordCount\":497,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/\",\"name\":\"PharmaCyte Biotech Reports Strong Cash and Asset Position - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-11-13T14:28:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-reports-strong-cash-and-asset-position\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PharmaCyte Biotech Reports Strong Cash and Asset Position\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PharmaCyte Biotech Reports Strong Cash and Asset Position - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/","og_locale":"en_US","og_type":"article","og_title":"PharmaCyte Biotech Reports Strong Cash and Asset Position - Market Newsdesk","og_description":"PharmaCyte Biotech Reports Strong Cash and Asset Position As reported in its Form 10-Q for the latest quarter, the Company maintains more than $17 million in cash with total assets over $36 million LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (\u201cPharmaCyte\u201d or the \u201cCompany\u201d) today provided an update on its financial position. As reported in the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 (PMCB\u2019s fiscal year ends April 30), PharmaCyte held total assets of approximately $36.7 million, including approximately $17.7 million in cash and cash equivalents. Stockholders\u2019 equity totaled approximately $27.5 million as of July 31, 2026. PharmaCyte has approximately 566,000 shares of common stock outstanding. \u201cOur balance sheet is the foundation of PharmaCyte\u2019s … Continue reading \"PharmaCyte Biotech Reports Strong Cash and Asset Position\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-13T14:28:49+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PharmaCyte Biotech Reports Strong Cash and Asset Position","datePublished":"2026-11-13T14:28:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/"},"wordCount":497,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/","name":"PharmaCyte Biotech Reports Strong Cash and Asset Position - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-11-13T14:28:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261113547352r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-reports-strong-cash-and-asset-position\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PharmaCyte Biotech Reports Strong Cash and Asset Position"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1020953"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020953\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1020953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1020953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1020953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}